Expert discusses what is on the horizon for stone disease in coming years

“As people think about how we can do stone surgery more effectively, less morbidly for our patients, and less invasively, I think we're going to see robots enter our picture,” says Thomas Chi, MD.

Related Videos

Related Content

Advertisement

December 19th 2024

FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1

Hannah Clarke

The redePHine trial is expected to launch in the first half of 2025.

May 23rd 2022

Destigmatizing Urology: Dr. Pruthi discusses mental health

Urology Times staff

“I think we often encourage our patients to share concerns about depression, anxiety, and other mental health conditions, yet are less likely ourselves to seek help due to this issue of stigma,” says Raj S. Pruthi, MD, MHA, FACS.

September 4th 2024

FDA grants rare pediatric disease designation to YOLT-203 for primary hyperoxaluria type 1

Hannah Clarke

YOLT-203 is currently being assessed in the early phase 1 YOLT-203-101 trial.

February 17th 2022

Why kidney stones will become more prevalent over time

Urology Times staff

“The prevalence of kidney stones has increased over 80% over the last 30 years, and the epidemiology has changed such that it's beginning at a younger age now,” says Gregory Tasian, MD, MSc, MSCE.

August 28th 2024

Pelvic floor yoga is not superior to general physical conditioning for urinary incontinence

Hannah Clarke

Over 12 weeks, the average reduction in total UI frequency was 2.3 episodes per day among those in the pelvic yoga program compared with 1.9 episodes per day among those in the general physical conditioning program.

August 27th 2024

Increasing thiazide doses linked to fewer kidney stone events

Hannah Clarke

“What this means for patients is that thiazides remain an important option in the toolkit for preventing kidney stone recurrence,” says Ryan S. Hsi, MD, FACS.

Related Content

Advertisement

December 19th 2024

FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1

Hannah Clarke

The redePHine trial is expected to launch in the first half of 2025.

May 23rd 2022

Destigmatizing Urology: Dr. Pruthi discusses mental health

Urology Times staff

“I think we often encourage our patients to share concerns about depression, anxiety, and other mental health conditions, yet are less likely ourselves to seek help due to this issue of stigma,” says Raj S. Pruthi, MD, MHA, FACS.

September 4th 2024

FDA grants rare pediatric disease designation to YOLT-203 for primary hyperoxaluria type 1

Hannah Clarke

YOLT-203 is currently being assessed in the early phase 1 YOLT-203-101 trial.

February 17th 2022

Why kidney stones will become more prevalent over time

Urology Times staff

“The prevalence of kidney stones has increased over 80% over the last 30 years, and the epidemiology has changed such that it's beginning at a younger age now,” says Gregory Tasian, MD, MSc, MSCE.

August 28th 2024

Pelvic floor yoga is not superior to general physical conditioning for urinary incontinence

Hannah Clarke

Over 12 weeks, the average reduction in total UI frequency was 2.3 episodes per day among those in the pelvic yoga program compared with 1.9 episodes per day among those in the general physical conditioning program.

August 27th 2024

Increasing thiazide doses linked to fewer kidney stone events

Hannah Clarke

“What this means for patients is that thiazides remain an important option in the toolkit for preventing kidney stone recurrence,” says Ryan S. Hsi, MD, FACS.